kanitinib (CX1003) / Konruns Pharma - LARVOL DELTA

Dose-dependent efficacy of CX1003 in NSCLC immunotherapy: High dose for T cell response, low dose for apoptosis. (PubMed, Int Immunopharmacol) - "Both high and low doses of CX1003 enhance the efficacy of PD-L1 blockade in NSCLC, albeit through distinct mechanisms. High-dose CX1003 enhance the efficacy via inducing the T cell-mediated immune response, whereas low dose augment efficacy by promoting apoptosis. These findings provide rationale for treating NSCLC patients with the combination therapy."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD8 • MAP2K2

A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=126 | Recruiting | Sponsor: Beijing Konruns Pharmaceutical Co., Ltd. | Trial completion date: Nov 2022 ➔ Dec 2025 | Trial primary completion date: Nov 2022 ➔ Oct 2025

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor